Skip to Content
Biotechnology and health

Novavax has announced encouraging early results for its experimental coronavirus vaccine

All of the 131 volunteers who received the vaccine produced a high level of antibodies against covid-19.
August 5, 2020
Novavax

The news: Maryland biotechnology company Novavax has announced encouraging results from a preliminary study of its experimental coronavirus vaccine. The trial enrolled 131 healthy volunteers in Australia, gave them either a placebo or one of four escalating doses of its vaccine, and found that everyone who received the vaccine produced a high level of antibodies against covid-19. Novavax signed a deal last month to receive $1.6 billion in funding as part of the US federal government’s “Operation Warp Speed” program to develop a covid-19 vaccine.

Any side effects? About 80% volunteers experienced pain and tenderness at the injection site, while more than 60% had other side effects like fatigue and headaches. Most reactions were mild, but eight patients had severe side effects. Novavax says no one was hospitalized as a result, and all of the reactions disappeared after a few days.

Some provisos: As with any Phase I trial, the aim was to establish the safety rather than the efficacy of the vaccine. The data has been published on a preprint server, which means it hasn’t been peer-reviewed yet. Much like vaccine study results recently published by the Oxford/AstraZeneca team, and the Moderna trial, it’s too early to draw firm conclusions about whether the vaccine will protect against coronavirus long-term. That’s why Moderna and AstraZeneca are now enrolling tens of thousands of volunteers for the next stage of trials, when we’ll get a clearer picture of just how likely these vaccines are to work.

The bigger picture: AstraZeneca’s biopharma lead, Mene Pangalos, has warned that, rather than conferring permanent protection, a covid-19 vaccine may only have an effect for a year or two. There are more than 150 vaccines being developed around the world, with at least 25 already in human trials. Given the virus has infected 18.5 million people globally and killed over 700,000, the pressure is on to find a viable solution—although scientists warn that clinical safety cannot be compromised in the face of political and nationalistic pressure.

Deep Dive

Biotechnology and health

The Biggest Questions: What is death?

New neuroscience is challenging our understanding of the dying process—bringing opportunities for the living.

Some deaf children in China can hear after gene therapy treatment

After deafness treatment, Yiyi can hear her mother and dance to the music. But why is it so noisy at night?

Scientists just drafted an incredibly detailed map of the human brain

A massive suite of papers offers a high-res view of the human and non-human primate brain.

Three people were gene-edited in an effort to cure their HIV. The result is unknown.

CRISPR is being used in an experimental effort to eliminate the virus that causes AIDS.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.